comparemela.com

Latest Breaking News On - Point pharmaceuticals - Page 8 : comparemela.com

Legato Capital Management LLC Has $1.37 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Legato Capital Management LLC lessened its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 23.3% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 59,347 shares of the company’s stock after selling 18,054 shares during the period. Legato Capital Management LLC owned […]

Darioa-paggiarino
News-ratings-for-eyepoint-pharmaceuticals-daily
Nasdaq
Quarter-for-eyepoint-pharmaceuticals
Investment-advisers
Eyepoint-pharmaceuticals
Securities-exchange-commission
Jpmorgan-chase-co
Toth-financial-advisory-corp
Lazard-asset-management
Eyepoint-pharmaceuticals-inc

Legato Capital Management LLC Sells 18,054 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Legato Capital Management LLC trimmed its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 23.3% during the fourth quarter, HoldingsChannel reports. The fund owned 59,347 shares of the company’s stock after selling 18,054 shares during the quarter. Legato Capital Management LLC’s holdings in EyePoint Pharmaceuticals were worth $1,372,000 at the end […]

Darioa-paggiarino
Eyepoint-pharmaceuticals-company-profile
Eyepoint-pharmaceuticals-stock-down
Legato-capital-management
Goldman-sachs-group-inc
Insider-activity-at-eyepoint-pharmaceuticals
Jpmorgan-chase-co
Vanguard-group-inc
Eyepoint-pharmaceuticals-inc
News-ratings-for-eyepoint-pharmaceuticals-daily
Nasdaq

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $24.40

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $24.40
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Darioa-paggiarino
Toth-financial-advisory-corp
Investment-advisers
Nasdaq
Jpmorgan-chase-co
Insider-activity-at-eyepoint-pharmaceuticals
News-ratings-for-eyepoint-pharmaceuticals-daily
Tower-research-capital
Eyepoint-pharmaceuticals-stock-down
Schonfeld-strategic-advisors
Eyepoint-pharmaceuticals

EyePoint Pharmaceuticals (NASDAQ:EYPT) Announces Quarterly Earnings Results

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) issued its earnings results on Thursday. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.27, Zacks reports. The firm had revenue of $14.03 million during the quarter, compared to the consensus estimate of $8.71 million. EyePoint Pharmaceuticals had a negative return […]

Darioa-paggiarino
Hedge-funds-weigh-in-on-eyepoint-pharmaceuticals
Eyepoint-pharmaceuticals-inc
Eyepoint-pharmaceuticals-price-performance
Earnings-history-for-eyepoint-pharmaceuticals
Exome-asset-management
Voloridge-investment-management
News-ratings-for-eyepoint-pharmaceuticals-daily
Vanguard-group-inc
Jpmorgan-chase-co
Barclays-plc

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%

One thing we could say about the analysts on EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) - they aren't optimistic.

Eyepoint-pharmaceuticals
Point-pharmaceuticals

vimarsana © 2020. All Rights Reserved.